Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quercetin in Idiopathic Pulmonary Fibrosis and Non-Idiopathic Pulmonary Fibrosis
NCT07466420Recruiting
- Sponsor
- Katerina M. Antoniou
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Randomised trial in idiopathic pulmonary fibrosis (IPF) and fibrotic interstitial lung disease (ILD) (2 arms), sponsored by Katerina M. Antoniou. Primary endpoints: Change in Blood Leukocyte Telomere length at Week 32, Change in Fractional Exhaled Nitric Oxide at Week 32 and 4 more. Started Jan 2026; status: recruiting.
02
Conditions
idiopathic pulmonary fibrosis (IPF)fibrotic interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT07466420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07466420.